Sunday, May 03, 2020

ARDS is a Common Cause of Death in Critically Ill Coronavirus Patients—Here's Why

The majority of people—about 80% according to research—only suffer mild symptoms with COVID-19. Others may require hospitalization—but for some patients, the new coronavirus can be deadly.

One life-threatening complication that can arise is acute respiratory distress syndrome, commonly referred to as ARDS. And new research from the JAMA Internal Medicine suggests that more than 40% of individuals in the study hospitalized for severe and critical COVID-19 developed ARDS—and over 50% of those diagnosed died from the disease.


What exactly is ARDS?

The American Lung Association (ALA) says ARDS is a rapidly progressive disease that can occur in critically ill patients—most notably now, in those diagnosed with severe illness resulting from coronavirus.

ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease), and, per the ALA, those with ARDS often have severe shortness of breath, cough, and fever. Fast heart rate and rapid breathing also shows up in ARDS patients, along with chest pain, particularly during inhaling. "ARDS is manifested as rapid and progressive shortness of breath," Shervin Takyar, MD, PhD, a Yale Medicine pulmonologist, tells Health.

The disease can be caused by direct injuries to the lungs (pneumonia, aspiration, near drowning, or smoke inhalation), or indirect injuries to the lungs (sepsis, blood transfusions, or medication reactions). While many still won't develop ARDS even with those injuries, some risk factors—like a smoking history, oxygen use, obesity, and recent chemotherapy—can increase a person's risk of developing the disease.

How is ARDS treated and what are the complications?

In most cases of ARDS, patients will have to be supported by supplemental oxygen and mechanical ventilation soon after the start of their symptoms, says Dr. Takyar. When their blood oxygen levels remain low, patients may be flipped on their stomachs—into a prone position—to get more oxygen into their blood, says the ALA.

Proning is literally turning people over on their bellies, instead of having them on their back on a ventilator, Jeanne Marrazzo, MD, professor of medicine in the infectious diseases division at the University of Alabama at Birmingham, explained during a recent media briefing sponsored by the Infectious Diseases Society of America. "And when you do that in a cycle, you get better oxygenation, and the outcomes are incredible," per Dr. Marrazzo.


In some cases, if inflammation and fluid in the lungs persists, some ARDS patients will develop scarring of the lungs (the fibrotic stage of ARDS). In others, the lung or lungs can eventually pop and deflate, leading to a pneumothorax or a collapsed lung.

According to the American Thoracic Society, the death rate for ARDS shows that it has a mortality rate of 30-40% of those diagnosed with the disease. In those who recover, lung function gradually improves over six months to a year, and even then they're left with significant scarring and lower than normal lung volumes. Those who survive ARDS can also go on to suffer from anxiety, depression, and PTSD from the impaired quality of life and lung function, Gregory P. Cosgrove, MD, Chief Medical Officer of the Pulmonary Fibrosis Foundation, tells Health.


How does COVID-19 lead to ARDS?

Similar to many other viruses, coronaviruses—including the novel coronavirus, or SARS-CoV-2—can infect and damage the lung cells, setting the stage for the occurrence of ARDS, explains Dr. Takyar. “It is thought that the infection-induced damage and inflammation cause a malfunction of the lung vasculature [the pulmonary vessels within the lungs]," he says. When that happens, the exchange of oxygen within the body is impaired. Among viruses, the ones that cause pneumonia (like COVID-19) are more likely to cause ARDS.

When patients are in the late stages of novel coronavirus infection—after severe damage has already been done to their lungs—their body will try to fight off the virus by sending immune cells to the lungs, which is what ultimately causes the inflammatory reaction, explains Dr. Takyar. In fact, ARDS in coronavirus “seems to be less directly due to the virus itself and more related to inflammation, or the body’s response to the virus,” adds Jaimie Meyer, MD, a Yale Medicine infectious disease specialist. 


While experts are still in the early stages of learning about COVID-19, research surrounding ARDS and coronavirus has found that the two often go hand-in-hand. According to the earlier JAMA study, researchers also concluded that an older age translated to a higher risk factor of developing ARDS and dying, "likely owing to less rigorous immune response," per the study authors. Additionally, the authors noted that if an ARDS patient was running a higher fever, they were more likely to recover, due to the body fighting off the infection.

An alternate study published in January in The Lancet also found that ARDS can develop incredibly quickly in critically ill coronavirus patients. Those researchers found that ARDS developed in 17% of those diagnosed COVID-19, among whom, 11 worsened in a short period of time and died of either ARDS or other serious complications like multiple organ failure.

The information in this story is accurate as of press time. However, as the situation surrounding COVID-19 continues to evolve, it's possible that some data have changed since publication. While Health is trying to keep our stories as up-to-date as possible, we also encourage readers to stay informed on news and recommendations for their own communities by using the CDC, WHO, and their local public health department as resources.


This is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.     

https://gscrochetdesigns.blogspot.com. one can see my crochet creations  
https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes    
https://kneereplacement-stickclub.blogspot.com. for info on knee replacement

Labels: , , , , , , , ,

Could the Heartburn Drug Famotidine Help Fight COVID-19? Here's What We Know Right Now

Scientists continue to look into potential treatments for COVID-19, and the latest to be touted is famotidine, which is the active ingredient in the popular over-the-counter heartburn medication Pepcid.

Kevin Tracey, MD, president of Feinstein Institutes for Medical Research at Northwell Health in New York City, told Science that preliminary results of a clinical trial of famotidine could be ready in the next few weeks. The trials have been underway since April 7 at Northwell, one of the largest hospital systems in New York City. As of April 25, 1,174 patients—including 187 who were critically ill—have taken part.

Dr. Tracey said that earlier in the outbreak, doctors who worked with coronavirus patients in Wuhan, China discovered that although one in five COVID-19 patients over the age of 80 died, many of those who survived had been taking heartburn meds. Studies on the Chinese patients have not yet been published, but the findings were enough to encourage US scientists to explore famotidine’s potential. 
Trialling an OTC drug intended to relieve heartburn might seem a bit out of left field, considering that COVID-19 is a disease affecting the lungs and airways. But Dr. Tracey pointed out in the Science interview that there are “many examples in the history of medicine where a drug that was designed for one purpose turns out to have an effect in another disease.”

The case for trialling famotidine was bolstered by a computer model used by Florida-based Alchem Laboratories to compile a list of existing drugs that might fight coronavirus. Famotidine showed up near the top of the list, and the company received a $20.7 million contract to conduct the trial at Northwell from the US Biomedical Advanced Research and Development Authority (BARDA).

According to Dr. Tracey, famotidine was flagged because—in theory—the drug is structured in a way that could prevent the coronavirus from replicating, in the same way that protease inhibitors, which are used to treat HIV, stop that virus from replicating.

“Famotidine is a histamine receptor blocker,” Solomon L. Lerer, MD, a gastroenterologist in Aventura, Florida, tells Health. Specifically, the compound blocks the H2 receptors that play a role in producing acid in the stomach, which can lead to heartburn, a main symptom of gastroesophageal reflux disease (GERD). Famotidine is considered a relatively safe drug, Dr. Lerer adds, but side effects can include diarrhea, muscle aches, and headaches. 

“Famotidine is most commonly used to treat gastroesophageal reflux disease,” Abraham Khan, MD, director of the Center for Esophageal Diseases at NYU Langone Health, tells Health. “Often, it works best in patients with mild GERD symptoms that do not need a daily stronger acid suppressive medication, such as a proton pump inhibitor (PPI).”

Dr. Khan says that “it is not intuitive to think that famotidine would be a successful treatment for COVID-19 patients.” However, based on the limited retrospective evidence on outcomes made available so far, as well as the possibility that the drug may bind to a viral enzyme to interfere with its replication, he believes it’s worth an official trial study to see if it can be a treatment option for COVID-19.

“The evidence from China is anecdotal, and a double-blind study is needed to really determine the effectiveness of famotidine," adds Dr. Lerer.

The patients participating in the clinical trial at Northwell Health include a group who are also taking the anti-malarial drug hydroxychloroquine, as well as patients who are on hydroxychloroquine only. Hundreds of patients treated early on in the COVID-19 outbreak are also part of the trial.

Hydroxychloroquine is the drug hailed as a “game changer” by President Trump in a coronavirus task force briefing on March 20. However, preliminary results from a study sponsored by the New York State Department of Health, which looked at about 600 patients at 22 hospitals in the greater New York City area, suggest that hydroxychloroquine "didn't really have much of an effect on the recovery rate,” according to New York Governor Andrew Cuomo, as reported by CNN.

The same discouraging result could come out of the famotidine study. Keep in mind that this is a trial, and no drug treatment—famotidine or something else—will be approved to treat COVID-19 anytime soon.

In the meantime, Dr. Lerer warns that people should absolutely not rush out to buy the drug from their local drugstore. “It's important to be aware that in this current Northwell study, patients are taking mega doses of famotidine intravenously and are not taking pills orally. There is always a possibility that mega doses of any drug can have potential negative long-term side effects,” he says. And if the general public starts stockpiling Pepcid, heartburn patients who really need it could suffer.

The information in this story is accurate as of press time. However, as the situation surrounding COVID-19 continues to evolve, it's possible that some data have changed since publication. While Health is trying to keep our stories as up-to-date as possible, we also encourage readers to stay informed on news and recommendations for their own communities by using the CDC, WHO, and their local public health department as resources.


This is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.     

https://gscrochetdesigns.blogspot.com. one can see my crochet creations  
https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes    
https://kneereplacement-stickclub.blogspot.com. for info on knee replacement

Labels: , , , , , ,

Friday, December 28, 2018

Your brain rewards you twice per meal

Your brain rewards you twice per meal: When you eat and when food reaches your stomach

We know a good meal can stimulate the release of the feel-good hormone dopamine, and now a study in humans  suggests that dopamine release in the brain occurs at two different times: at the time the food is first ingested and another once the food reaches the stomach. 

"With the help of a new positron emission tomography (PET) technique we developed, we were not only able to find the two peaks of dopamine release, but we could also identify the specific brain regions that were associated with these releases," says senior author.
 
 "While the first release occurred in brain regions associated with reward and sensory perception, the post-ingestive release involved additional regions related to higher cognitive functions."
 
In the study, 12 healthy volunteers received either a palatable milkshake or a tasteless solution while PET data were recorded. Interestingly, the subjects' craving or desire for the milkshake was proportionally linked to the amount of dopamine released in particular brain areas at the first tasting. But the higher the craving, the less delayed post-ingestive dopamine was released.
 
"On one hand, dopamine release mirrors our subjective desire to consume a food item. On the other hand, our desire seems to suppress gut-induced dopamine release," says group leader, who is co-first author on the study.
 
Suppression of gut-induced release could potentially cause overeating of highly desired food items. "We continue to eat until sufficient dopamine was released," The author says but adds that this hypothesis remains to be tested in further studies.
 
Earlier experiments have demonstrated gut-induced dopamine release in mice, but this is the first time it has been shown in humans.

Labels: , , , , ,

Tuesday, October 03, 2017

AN HOUR OF EXERCISE PER WEEK, CUTS YOUR RISK OF DEPRESSION GREATLY

One hour of exercise a week can help prevent  depression according to a study. 

Researchers studied more than 30,000 people and found that 12 percent of cases of depression could have been prevented through exercise because of the 'feel-good' endorphins that are released into the brain.

These endorphins help lessen negative emotions and relax the person who is exercising. 

More than 300 million people worldwide suffer from depression and that number is only anticipated to grow as sedentary behavior rises.

The study recommends for health experts to use this information to alter their treatment options for people with depression. 

Researchers analyzed 33,808  adults on their levels of exercise and symptoms of depression. 

These adults were monitored over 11 years to see how exercising had an impact on their mental health. 

The research team found that 12 percent of cases of depression could have been prevented if participants undertook just one hour of physical activity every week.

'We've known for some time that exercise has a role to play in treating symptoms of depression, but this is the first time we have been able to quantify the preventative potential of physical activity in terms of reducing future levels of depression,' said the lead author. 

'These findings are exciting because they show that even relatively small amounts of exercise - from one hour per week - can deliver significant protection against depression.

Natural chemicals in the brain are released during exercise to give the person a sense of well-being. 

This can help someone cope with anxiety and depression if exercise is done for as little as one hour per week.

'These results highlight the great potential to integrate exercise into individual mental health plans and broader public health campaigns,' author said. 

If we can find ways to increase the population's level of physical activity even by a small amount, then this is likely to bring substantial physical and mental health benefits.'

Participants in the study were asked a baseline of the exercise they participated in and the intensity. 

This was then followed up with a questionnaire to gauge the participants level of anxiety and depression.  

Variables that were accounted for were socio-economic and demographic factors, substance use, body mass index, new onset physical illness and perceived social support.

Results showed that people who reported doing no exercise at all at baseline were 44 percent more likely to develop depression compared to those who were exercising one to two hours a week.

However, these benefits did not carry through to protecting against anxiety, with no association identified between level and intensity of exercise and the chances of developing the disorder.

More than 300 million people worldwide suffer from depression and an average of 800,000 people commit suicide every year.

Researchers said this study can help mental health experts when dealing with people with depression in terms of treatment options.

'Most of the mental health benefits of exercise are realized within the first hour undertaken each week,' said the author.

'With sedentary lifestyles becoming the norm worldwide, and rates of depression growing, these results are particularly pertinent as they highlight that even small lifestyle changes can reap significant mental health benefits.' 

THIS IS ONLY FOR INFORMATION, ALWAYS CONSULT YOU PHYSICIAN BEFORE HAVING ANY PARTICULAR FOOD/ MEDICATION/EXERCISE/OTHER REMEDIES. PS- THOSE INTERESTED IN RECIPES ARE FREE TO VIEW MY BLOG-                      
HTTP:GSEASYRECIPES.BLOGSPOT.COM/
FOR INFO ABOUT KNEE REPLACEMENT, YOU CAN VIEW MY BLOG-                                                                           
HTTP://KNEE REPLACEMENT-STICK CLUB.BLOGSPOT.COM/
FOR CROCHET DESIGNS

HTTP://MY CROCHET CREATIONS.BLOGSPOT.COM

Labels: , , , , , , ,